Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Stage III Ovarian Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    145 result(s) found for: Stage III Ovarian Cancer. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2006-004484-54 Sponsor Protocol Number: IP-CAT-OC-02 Start Date*: 2007-08-30
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer
    Medical condition: Epithelial Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033162 Ovarian epithelial cancer stage II LLT
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    9.1 10033164 Ovarian epithelial cancer stage IV LLT
    9.1 10033161 Ovarian epithelial cancer stage I LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001506-25 Sponsor Protocol Number: NN028-1802 Start Date*: Information not available in EudraCT
    Sponsor Name:Novo Nordisk A/S
    Full Title: An open–label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients with Persistent or Progressive Disease after, or Relapse within One Year of, Completion of Stand...
    Medical condition: advanced epithelial Ovarian Cancer stage IIB-IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033162 Ovarian epithelial cancer stage II LLT
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    9.1 10033164 Ovarian epithelial cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005674-31 Sponsor Protocol Number: HIPEC_ovaio Start Date*: 2007-10-30
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGICAL DEBULKING AND INTRAPERITONEAL CHEMOHYPERTHERMIA FOR STAGE III OVARIAN CANCER. A PROSPECTIVE PHASE II STUDY
    Medical condition: ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004429-41 Sponsor Protocol Number: BAY43-9006/12007 Start Date*: 2008-10-03
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a ...
    Medical condition: The study population will include patients with FIGO stage III or IV ovarian cancer or primary peritoneal cancer who have had extensive debulkment surgery and who have achieved a clinical complete ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033164 Ovarian epithelial cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033163 Ovarian epithelial cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed) FI (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-000126-31 Sponsor Protocol Number: 1401 Start Date*: 2006-06-24
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: A phase II trial of carboplatin and paclitaxel compared with carboplatin or gemcitabine paclitaxel "induction" followed by carboplatin/paclitaxel/gemcitabine in patients with suboptimally resected ...
    Medical condition: Epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033163 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002663-26 Sponsor Protocol Number: AEZS-108-040 Start Date*: 2007-12-05
    Sponsor Name:AEterna Zentaris GmbH
    Full Title: Antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors
    Medical condition: Histologically confirmed malignancy of ovary or endometrium that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective and LHR...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007069 Cancer of endometrium stage III LLT
    9.1 10007065 Cancer of endometrium recurrent LLT
    9.1 10007070 Cancer of endometrium stage IV LLT
    9.1 10057529 Ovarian cancer metastatic LLT
    9.1 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003346-17 Sponsor Protocol Number: M17OVH Start Date*: 2019-04-18
    Sponsor Name:NKI-AVL
    Full Title: Phase III Randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: OVHIPEC-2
    Medical condition: stage III epithelial ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005091-36 Sponsor Protocol Number: 2020-005091-36 Start Date*: 2021-08-30
    Sponsor Name:Stichting Catharina Hospital
    Full Title: Signal TrAnsduction Pathway activity analysis for OVarian cancER treatment. STAPOVER study
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070905 Ovarian cancer stage I PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070906 Ovarian cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007107 Cancer of ovary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026310 Malignant neoplasm of ovary LLT
    Population Age: Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001982-34 Sponsor Protocol Number: MOVES Start Date*: 2022-04-19
    Sponsor Name:Pirkanmaan hyvinvointialue
    Full Title: Measuring Oncogical Value of Exercise and Statin
    Medical condition: Metastatic breast, ovarian, kidney and prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023404 Kidney cancer stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023405 Kidney cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005504-13 Sponsor Protocol Number: 2006.444/37 Start Date*: 2007-03-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: ETUDE MULTICENTRIQUE FAG-3 : TRAITEMENT PAR CARBOPLATINE DES PATIENTES DE PLUS DE 70 ANS ATTEINTES DE CANCER AVANCE DE L’OVAIRE : PREDICTION DE LA VULNERABILITE INDIVIDUELLE PAR UNE EVALUATION PSY...
    Medical condition: cancer avancé de l'ovaire
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057529 Ovarian cancer metastatic LLT
    Population Age: Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001006-28 Sponsor Protocol Number: 20170770 Start Date*: 2019-09-13
    Sponsor Name:Amgen Inc.
    Full Title: PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of No...
    Medical condition: non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) AT (Completed) HU (Completed) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003472-52 Sponsor Protocol Number: YO39523 Start Date*: 2017-07-21
    Sponsor Name:Roche Farma S.A.U que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STA...
    Medical condition: Ovarian cancer, fallopian tube cancer, primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) NO (Completed) CZ (Completed) DE (Completed) AT (Completed) PL (Completed) FI (Completed) GR (Prematurely Ended) DK (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001323-38 Sponsor Protocol Number: SOV02 Start Date*: 2013-08-30
    Sponsor Name:SOTIO a.s.
    Full Title: A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with rel...
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003043-29 Sponsor Protocol Number: MITO-16/MaNGO-OV2 Start Date*: 2012-09-24
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: A multicenter study in patients with stage III-IV epithelial ovarian cancer treated with carboplatin/paclitaxel with bevacizumab: clinical and biological prognostic factors
    Medical condition: advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001325-24 Sponsor Protocol Number: SOV03 Start Date*: 2013-08-30
    Sponsor Name:SOTIO a.s.
    Full Title: A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy in women with relapsed platinum resistant epith...
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001112-53 Sponsor Protocol Number: 20101129 Start Date*: 2012-01-09
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, P...
    Medical condition: FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Completed) ES (Completed) BE (Completed) NL (Completed) AT (Completed) DK (Prematurely Ended) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003871-32 Sponsor Protocol Number: AL3818-US-002 Start Date*: 2021-11-11
    Sponsor Name:ADVENCHEN LABORATORIES, LLC
    Full Title: A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects...
    Medical condition: Recurrent or metastatic endometrial, ovarian, fallopian tube, primary peritoneal, or cervical carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019525-34 Sponsor Protocol Number: MO22923 Start Date*: 2010-12-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA
    Medical condition: EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CARCINOMA PRIMARY PERITONEAL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033128 Ovarian cancer LLT
    12.1 10052204 Ovarian carcinosarcoma LLT
    12.1 10016180 Fallopian tube cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Completed) FR (Completed) ES (Completed) LT (Completed) AT (Completed) LV (Completed) NL (Completed) IE (Completed) SE (Completed) EE (Completed) HU (Completed) IT (Completed) BG (Completed) DK (Completed) SI (Completed) GR (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004632-11 Sponsor Protocol Number: D081RC00001 Start Date*: 2018-12-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olapa...
    Medical condition: Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016186 Fallopian tube cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016187 Fallopian tube cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000509-31 Sponsor Protocol Number: 206-OC-202 Start Date*: 2007-10-10
    Sponsor Name:Biogen Idec Ltd
    Full Title: Estudio en fase 1/2, abierto, adaptativo, aleatorio de doxorrubicina liposómica con o sin M200 (volociximab) para el tratamiento de pacientes con cáncer de ovario epitelial avanzado o cáncer perito...
    Medical condition: Cáncer de ovario epitelial avanzado o cáncer peritoneal primario Advanced epithelial ovarian cancer or primary peritoneal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 23 08:36:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA